Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

p="name">Stephen Brannan, M.D., Central Nervous System Development Therapeutic Area Head, Takeda. "TOMMORROW is a significant study and represents a novel clinical milestone and trial for the Alzheimer's community as it evaluates pre-symptomatic patients."

About the TOMMORROW Trial
The TOMMORROW trial is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The trial will use a genetic–based biomarker risk assignment algorithm comprised of APOE and TOMM40 genotypes and age, which is being studied to determine the risk of individuals developing MCI due to AD within a five year period. Cognitively normal individuals assessed as low risk will be assigned to receive placebo. Cognitively normal individuals assessed as high risk will be assigned to AD-4833 or placebo. The study duration is approximately five years or the time needed to achieve 410 conversions to MCI due to AD in the high risk group. Approximately 5,800 cognitively normal individuals aged 65-83 at 50 centers worldwide will be randomized into the study. The study will recruit internationally from large, diverse, community-based populations.

The study has two objectives:

For the genetic-based biomarker risk assignment algorithm, the primary objective is to qualify the risk assignment algorithm for identification of subjects at high risk of developing MCI due to AD within the next five years. The primary endpoint for the risk assignment algorithm is time to diagnosis of MCI due to AD for placebo-treated, high-risk subjects versus placebo-treated, low-risk subjects.

For AD-4833, considered an investigational drug for this use, the primary objective is to evaluate the efficacy of AD-4833 versus placebo in delaying the onset of MCI due to AD in cognitively normal individuals assessed as high risk based on the risk assignment algorithm. The primary endpoint is time to diagnosis of MCI due to AD for AD-4833-treated subjects versus pl
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
(Date:10/1/2014)... ALTO, Calif. , Oct. 1, 2014  Varian ... that it will report results for the fourth quarter ... trading on Wednesday, October 22, 2014.  The news release ... interested parties at 2:00 p.m. PT.  The news release ... be available on the company website at: www.varian.com/investor ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... March 29, 2011 Konica Minolta Sensing Americas, Inc. ... color, light and shape, announces the launch of its ... the pharmaceutical industry at the 2011 Interphex show March ... Center. (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
... March 29, 2011 SinoFresh® HealthCare, Inc., (Pink Sheets: ... signed contracts with three high volume sales agencies. These ... boost to long term sales and distribution along the ... SinoFresh,s Antiseptic Homeopathic Nasal and Sinus Care Spray available ...
Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3SinoFresh HealthCare Signs Three Sale Marketing Agreements 2SinoFresh HealthCare Signs Three Sale Marketing Agreements 3
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater Toronto ... choice, is announcing a discounted cost on Botox units, ... “We’re doing this because we want to give as ... clinic in Toronto,” says Dr. Brian Sieber, founder of ... Aging Clinic, including laser facials, genesis laser facials, ...
(Date:10/1/2014)... October 01, 2014 Nordic Naturals ... a very special cause. The campaign—“Buy One Bottle. ... Paws for Veterans, a nonprofit organization that helps ... rescuing shelter dogs that would otherwise face euthanasia. ... products will support monthly donations of Nordic Naturals ...
(Date:10/1/2014)... 2014 Today marks the final day ... Institute in Oxnard and Woodland Hills, Calif., is in ... rehabilitation training. , “Speaking to this group of specialists ... to get the help and care they deserve,” Dr. ... previous dental work, providing cosmetic dentistry, correcting bite issues, ...
(Date:10/1/2014)... 2014 UP4 Probiotics will be donating ... to The National Network to End Domestic Violence ( ... was chosen through nationwide polling that took place during ... outlets. , “We are proud to have been ... every sale of UP4 Women’s Probiotics during the month ...
(Date:10/1/2014)... This weekend Pope Francis drew world-wide attention to ... to 40,000 seniors in St. Peter's Square in the Vatican, ... "Violence against the elderly is as inhuman as that against ... people just discarded, victims of an abandonment that is tantamount ... culture that is hurting our world so much," he said. ...
Breaking Medicine News(10 mins):Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 3
... white paper that examines various state initiatives to expand access ... and Congress in support of state efforts, was distributed today ... The paper, State Experimentation with Reforms to Expand Access to ... part of any state-based reform. It is a summary of ...
... Ill., Sept. 14 The board of,directors of Abbott ... share. This marks the 335th consecutive quarterly dividend ... is payable Nov. 15, 2007, to,shareholders of record at ... About Abbott Abbott (NYSE: ABT ) is ...
... 14 As the political turmoil,surrounding stem cells rages ... and treatment - that saved his life. John E. ... -, http://www.authorhouse.com ), recounts the courageous five-year battle the,author ... cancer. Settling into a comfortable retirement with his ...
... of Texas Medical Branch at Galveston are trying to ... can also be used to delay delivery in expectant ... would give hope to hundreds of thousands of women ... drug, Digibind, has been prescribed for over 20 years ...
... Sept. 14 People,s United,Financial (Nasdaq: PBCT ) ... Klein, had undergone surgery to address a recurrence of,cancer ... surgery. He reported,in an e-mail to all employees that ... bank in early October. He stated that he is ...
... - Philly-Area Employers Get Moving by Putting on ... AstraZeneca continues,its fight against sedentary lifestyles by ... in Philadelphia to promote,walking and other healthy habits ... a Start! "walkforce" team to participate in,today,s Philadelphia ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2Health News:AstraZeneca Joins Local Walking Movement 2Health News:AstraZeneca Joins Local Walking Movement 3Health News:AstraZeneca Joins Local Walking Movement 4
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... The 8180 Series customized ... for all your endoscopy video ... enhancement, and customized menus to ... needs. 8180 Series cameras are ...
... Camera System provides easy-to-use features, auto iris, ... The camera head construction is based on ... Camera System for Microscopic Application, Domestic (MS ... Unit (CCU) with power cord and video ...
... offers 800+ lines of resolution along with color ... white balance features in a user-friendly design. , ... includes: , (GS 9923) Camera Control Unit (CCU) ... head with 3 meter cable (10 ft.)(1/2" format ...
Medicine Products: